Press release

Centers for Medicare & Medicaid Services publish final rate of $192 for Epigenomics' colorectal cancer screening blood test Epi proColon®

Berlin (Germany) and San Diego, CA (U.S.A.), October 22, 2018 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced that the Centers for Medicare & Medicaid Services (CMS) published a final rate of $192 for Epi proColon, the first and only FDA-approved blood test for colorectal cancer screening.

This announcement confirms the preliminary gapfill rate as determined by the Medicare Administrative Contractors, published on June 11, 2018. The $192 per test rate will be included in the *2019 Clinical Laboratory Fee Schedule* that is expected to be published in November 2018.

"The final CMS rate of $192 is an important accomplishment for the company as it appropriately values our innovative blood-based colorectal cancer screening test," said Greg Hamilton, CEO of Epigenomics AG. "Medicare pricing sets a benchmark for value and it's an important component of our commercialization strategy."

About Epi proColon®

Epi proColon is indicated for colorectal cancer screening in average-risk patients who are unwilling or unable to perform colorectal cancer screening by colonoscopy and stool-based methods.

For patients, the test only requires a simple blood sample drawn as part of routine healthcare provider visits. There are no dietary restrictions or alterations in medication required for the test. The sample will be analyzed at a national or regional diagnostic laboratory.

For more information on Epi proColon, visit www.epiprocolon.com.

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epi proLung®, a blood-based test for lung cancer detection, has received CE mark in Europe.

For more information, visit www.epigenomics.com.

Contact in the U.S.
David Bull
Director of Marketing
Phone: 240.912.6430
David.Bull@Epigenomics.com

Contact Epigenomics AG

Peter Vogt
VP Corporate Communication & Investor Relations
Epigenomics AG
Geneststraße 5
10829 Berlin
Phone +49 (0) 30 24345 386
ir@epigenomics.com

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.